JMKX 1899
Alternative Names: HBI-2438; JMKX-1899Latest Information Update: 12 Jan 2024
At a glance
- Originator Jemincare
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 11 Oct 2023 Pharmacodynamics data from a preclinical studies in Cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)
- 03 Aug 2022 HUYABIO International plans a phase I trial for Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT05485974)
- 30 Nov 2021 JMKX 1899 licensed to HUYA Biosciences International worldwide (ADNM)